The effectiveness and safety study of topical corticosteroids for psoriasis in adolescent and adult population treatment

Authors

DOI:

https://doi.org/10.14739/2310-1210.2020.6.218458

Keywords:

psoriasis, topical corticosteroids, life quality

Abstract

 

Aim: to determine the efficacy and safety of clobetasol propionate compared with fluticasone propionate in the form of ointment for the treatment of psoriasis patients.

Materials and methods. A total of 65 psoriasis patients were included in the study, 40 healthy individuals were included in the control group, all aged 14 to 65. Psoriasis patients were divided into 2 therapeutic groups: I – received topical treatment with fluticasone propionate; II – with clobetasol propionate. The severity of psoriasis was assessed by BSA and PASI index. Assessment of itching severity was carried out by a ten-point visual analogue scale. The quality of life was assessed according to the Ukrainian version of DLQI questionnaire.

Results. PASI index averaged 16.50 ± 0.65 points, and BSA index was 9.30 ± 0.94 % in the examined patients before the treatment. On average, the DLQI index in patients with psoriasis before the treatment was 13.80 ± 0.27 points. PASI index was lower in psoriasis patients treated with clobetasol propionate compared with the therapeutic group I patients. The ΔPASI indicator (%) at the end of the treatment was significantly lower in patients from the I therapeutic group, compared with the group of patients who used clobetasol propionate for treatment of psoriasis. Patients who used clobetasol propionate had lower scores for pruritus and excoriation at the end of the treatment compared with patients from the I therapeutic group. The DLQI index at the end of the treatment was significantly higher in the I therapeutic group compared with its values in patients who used clobetasol propionate in the complex treatment.

Conclusions. The use of topical corticosteroid clobetasol propionate in the form of ointment is the effective treatment for psoriasis, which causes a rapid regression of psoriatic rashes, a decrease in PASI and BSA indices, a decrease in pruritus and its objective signs, and indirectly improves the quality of life.

References

Smith, C. H., Jabbar-Lopez, Z. K., Yiu, Z. Z., Bale, T., Burden, A. D., Coates, L. C., Cruickshank, M., Hadoke, T., MacMahon, E., Murphy, R., Nelson-Piercy, C., Owen, C. M., Parslew, R., Peleva, E., Pottinger, E., Samarasekera, E. J., Stoddart, J., Strudwicke, C., Venning, V. A., Warren, R. B., … Mohd Mustapa, M. F. (2017). British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177(3), 628-636. https://doi.org/10.1111/bjd.15665

Vence, L., Schmitt, A., Meadows, C. E., & Gress, T. (2015). Recognizing Guttate Psoriasis and Initiating Appropriate Treatment. The West Virginia Medical Journal, 111(4), 26-28.

Kui, R., Gál, B., Gaál, M., Kiss, M., Kemény, L., & Gyulai, R. (2016). Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. The Journal of Dermatology, 43(9), 1018-1023. https://doi.org/10.1111/1346-8138.13301

Sorensen, E. P., Algzlan, H., Au, S. C., Garber, C., Fanucci, K., Nguyen, M. B., & Gottlieb, A. B. (2016). Lower Socioeconomic Status is Associated With Decreased Therapeutic Response to the Biologic Agents in Psoriasis Patients. Journal of Drugs in Dermatology, 15(2), 147-153.

Kytaseviсh, Ya. F., & Mashtakova, I. A. (2012). Ratsional'nyi vybor topicheskogo steroida [Rational choise of the topical steroid]. Ukrainskyi zhurnal dermatolohii, venerolohii, kosmetolohii, (1), 55-58. [in Russian].

Reznichenko, N. (2015). Sovremennye podkhody k lecheniyu i profilaktike obostrenii psoriaticheskoi bolezni [Modern approaches to treatment and prophylaxis of exacerbations of psoriasis]. Dermatovenerologiya. Kosmetologiya, (1), 116-128. [in Russian].

Choi, J. W., Kim, B. R., Seo, E., & Youn, S. W. (2017). Identification of nail features associated with psoriasis severity. The Journal of Dermatology, 44(2), 147-153. https://doi.org/10.1111/1346-8138.13565

Armstrong, A. W., Siegel, M. P., Bagel, J., Boh, E. E., Buell, M., Cooper, K. D., Callis Duffin, K., Eichenfield, L. F., Garg, A., Gelfand, J. M., Gottlieb, A. B., Koo, J. Y., Korman, N. J., Krueger, G. G., Lebwohl, M. G., Leonardi, C. L., Mandelin, A. M., Menter, M. A., Merola, J. F., Pariser, D. M., … Van Voorhees, A. S. (2017). From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology, 76(2), 290-298. https://doi.org/10.1016/j.jaad.2016.10.017

Berth-Jones, J., Exton, L. S., Ladoyanni, E., Mohd Mustapa, M. F., Tebbs, V. M., Yesudian, P. D., & Levell, N. J. (2019). British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. British Journal of Dermatology, 180(6), 1312-1338. https://doi.org/10.1111/bjd.17587

Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D., Elewski, B. E., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Kavanaugh, A., Kiselica, M., Korman, N. J., Kroshinsky, D., Lebwohl, M., Leonardi, C. L., … Elmets, C. A. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 80(4), 1029-1072. https://doi.org/10.1016/j.jaad.2018.11.057

Di Lernia, V., & Bardazzi, F. (2016). Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy, 10, 533-539. https://doi.org/10.2147/DDDT.S82599

Elmets, C. A., Lim, H. W., Stoff, B., Connor, C., Cordoro, K. M., Lebwohl, M., Armstrong, A. W., Davis, D., Elewski, B. E., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Kroshinsky, D., Leonardi, C. L., Lichten, J., … Menter, A. (2019). Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, 81(3), 775-804. https://doi.org/10.1016/j.jaad.2019.04.042

Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., Ohtsuki, M., Flack, M., Geng, Z., Gu, Y., Valdes, J. M., Thompson, E. H. Z., & Bachelez, H. (2018). Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet, 392(10148), 650-661. https://doi.org/10.1016/s0140-6736(18)31713-6

Alinia, H., Moradi Tuchayi, S., Smith, J. A., Richardson, I. M., Bahrami, N., Jaros, S. C., Sandoval, L. F., Farhangian, M. E., Anderson, K. L., Huang, K. E., & Feldman, S. R. (2017). Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. British Journal of Dermatology, 176(3), 759-764. https://doi.org/10.1111/bjd.15085

Lewis, D. J., Chan, W. H., Hinojosa, T., Hsu, S., & Feldman, S. R. (2019). Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. Clinics in Dermatology, 37(2), 160-166. https://doi.org/10.1016/j.clindermatol.2019.01.011

Schlager, J. G., Rosumeck, S., Werner, R. N., Jacobs, A., Schmitt, J., Schlager, C., & Nast, A. (2016). Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews, (2), Article CD009687. https://doi.org/10.1002/14651858.CD009687.pub2

Sekhon, S., Jeon, C., Nakamura, M., Afifi, L., Yan, D., Wu, J. J., Liao, W., & Bhutani, T. (2018). Review of the mechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment, 29(3), 230-232. https://doi.org/10.1080/09546634.2017.1369494

Miller, J. A., & Munro, D. D. (1980). Topical Corticosteroids: Clinical Pharmacology and Therapeutic Use. Drugs, 19(2), 119-134. https://doi.org/10.2165/00003495-198019020-00004

Kleyn, E. C., Morsman, E., Griffin, L., Wu, J. J., Cm van de Kerkhof, P., Gulliver, W., van der Walt, J. M., & Iversen, L. (2019). Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. Journal of Dermatological Treatment, 30(4), 311-319. https://doi.org/10.1080/09546634.2019.1620502

Lebwohl, M. G., Sugarman, J. L., Gold, L. S., Pariser, D. M., Lin, T., Pillai, R., Martin, G., Harris, S., & Israel, R. (2019). Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 80(1), 282-285. https://doi.org/10.1016/j.jaad.2018.09.002

Downloads

How to Cite

1.
Reznichenko NY, Reznichenko YH. The effectiveness and safety study of topical corticosteroids for psoriasis in adolescent and adult population treatment. Zaporozhye Medical Journal [Internet]. 2020Dec.9 [cited 2024Jul.20];22(6). Available from: http://zmj.zsmu.edu.ua/article/view/218458

Issue

Section

Original research